GLP-1s: Weight down, but steps down too? The paradox clinicians face

GLP-1 receptor agonists, including agents like liraglutide, semaglutide, and tirzepatide, exert their primary effects by mimicking endogenous incretin hormones. This action enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways. These mechanisms collectively lead to reduced caloric intake and subsequent weight loss, a critical outcome for patients struggling with obesity and its associated comorbidities.

The profound impact on weight has made these drugs a cornerstone in managing metabolic disease. But the physiological changes induced by these agents extend beyond simple caloric restriction. Patients often report a significant decrease in appetite and an earlier onset of satiety, which can alter their relationship with food and, by extension, their energy expenditure. This shift can manifest as less spontaneous physical activity, even as weight declines. For a comprehensive guide to managing these conditions, clinicians may find the Oxford Handbook of Endocrinology and Diabetes a useful reference.

The Energy Balance Equation

Weight loss, regardless of the method, typically involves a reduction in overall energy expenditure. This is a well-established physiological response where the body attempts to conserve energy in the face of reduced caloric intake. With GLP-1 agonists, the primary driver of weight loss is often a substantial reduction in food intake, leading to a negative energy balance. This reduction in intake can be so effective that patients may feel less inclined to engage in physical activity, perceiving less need to "burn off" calories.

The decrease in physical activity is not necessarily a direct pharmacological effect of the GLP-1 agonist itself. Rather, it appears to be a behavioural adaptation to the altered metabolic state and reduced hunger signals. Patients may simply feel less energetic or motivated to move when their caloric intake is significantly lower, or they may feel satisfied with their weight loss progress and inadvertently deprioritise exercise. This observation aligns with some of our previous coverage on exercise patterns in patients initiating GLP-1s.

Maintaining Muscle Mass and Function

A critical consideration in any weight loss strategy is the preservation of lean muscle mass. While GLP-1 agonists are highly effective at reducing fat mass, some studies indicate that a proportion of the weight lost can be lean body mass. Reduced physical activity exacerbates this issue, as muscle tissue is maintained through regular use. Loss of muscle mass can have significant long-term implications, including reduced metabolic rate, decreased strength, and impaired physical function, particularly in older adults.

Clinicians must therefore counsel patients on the importance of resistance training and regular aerobic exercise to mitigate muscle loss and maintain overall physical fitness. The goal of obesity management extends beyond mere weight reduction; it encompasses improving body composition, functional capacity, and metabolic health. Ignoring the physical activity component risks undermining some of the broader health benefits of weight loss.

Addressing the Behavioural Component

The challenge lies in integrating pharmacotherapy with lifestyle interventions. While GLP-1 agonists provide a powerful tool for appetite control, they do not inherently promote physical activity. This means that behavioural support for exercise remains essential for preserving lean body mass and functional capacity. Patients need clear guidance on how to incorporate regular movement into their routines, even when they feel less driven by hunger or the immediate need to lose more weight.

This requires a proactive approach from healthcare providers, moving beyond simply prescribing the medication. Discussions should include setting realistic activity goals, exploring enjoyable forms of exercise, and addressing potential barriers to physical activity. The long-term success of weight management often depends on sustained lifestyle changes, and physical activity is a non-negotiable component of that equation. Without it, patients risk post-GLP-1 weight regain and a decline in overall physical resilience.

The Unanswered Questions

The precise mechanisms linking GLP-1 agonist use to reduced physical activity require further investigation. Is it purely a behavioural response to reduced hunger, or are there subtle central nervous system effects that influence motivation or energy levels? Understanding these nuances could inform better patient counselling strategies and potentially lead to adjunctive therapies or exercise protocols tailored for patients on these medications.

For now, the message is clear: weight loss with GLP-1s is effective, but it does not absolve patients or clinicians from the responsibility of promoting and maintaining physical activity. The full health benefits of weight reduction are realised when accompanied by improved fitness and preserved muscle mass. The next wave of research should focus on optimising these combined approaches.